These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 34626096)

  • 1. Chronic long-COVID syndrome: A protracted COVID-19 illness with neurological dysfunctions.
    Baig AM
    CNS Neurosci Ther; 2021 Dec; 27(12):1433-1436. PubMed ID: 34626096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nervous system consequences of COVID-19.
    Spudich S; Nath A
    Science; 2022 Jan; 375(6578):267-269. PubMed ID: 35050660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses.
    Song WJ; Hui CKM; Hull JH; Birring SS; McGarvey L; Mazzone SB; Chung KF
    Lancet Respir Med; 2021 May; 9(5):533-544. PubMed ID: 33857435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic.
    Dewanjee S; Vallamkondu J; Kalra RS; Puvvada N; Kandimalla R; Reddy PH
    Mol Neurobiol; 2021 Sep; 58(9):4694-4715. PubMed ID: 34169443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Review on Neuro-COVID-19 Pathophysiology and Clinical Consequences.
    Jafari Khaljiri H; Jamalkhah M; Amini Harandi A; Pakdaman H; Moradi M; Mowla A
    Neurotox Res; 2021 Oct; 39(5):1613-1629. PubMed ID: 34169404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-COVID-19 syndrome: epidemiology, diagnostic criteria and pathogenic mechanisms involved.
    Carod-Artal FJ
    Rev Neurol; 2021 Jun; 72(11):384-396. PubMed ID: 34042167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation at the crossroads of COVID-19, cognitive deficits and depression.
    Lyra E Silva NM; Barros-Aragão FGQ; De Felice FG; Ferreira ST
    Neuropharmacology; 2022 May; 209():109023. PubMed ID: 35257690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?
    Ferini-Strambi L; Salsone M
    J Neurol; 2021 Feb; 268(2):409-419. PubMed ID: 32696341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Underlying Causes and Treatment Modalities for Neurological Deficits in COVID-19 and Long-COVID.
    Baig AM; Greig NH; Gerlach J; Salunke P; Fabrowski M; Viduto V; Ali T
    ACS Chem Neurosci; 2022 Oct; 13(20):2934-2938. PubMed ID: 36190929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Call for correction: Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis.
    Hagiya H; Otsuka Y; Otsuka F
    J Neurol Sci; 2022 May; 436():120232. PubMed ID: 35339066
    [No Abstract]   [Full Text] [Related]  

  • 11. The immunology and immunopathology of COVID-19.
    Merad M; Blish CA; Sallusto F; Iwasaki A
    Science; 2022 Mar; 375(6585):1122-1127. PubMed ID: 35271343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Update 2021: COVID-19 from the perspective of neurology].
    Simon OJ; Menzler K; Timmermann L
    Dtsch Med Wochenschr; 2021 Jul; 146(13-14):918-923. PubMed ID: 34256409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-COVID: neurological manifestations and management.
    Williams S; Wynford-Thomas R; Robertson NP
    J Neurol; 2021 Dec; 268(12):4915-4917. PubMed ID: 34674007
    [No Abstract]   [Full Text] [Related]  

  • 14. Emerging potential mechanisms and predispositions to the neurological manifestations of COVID-19.
    Jesuthasan A; Massey F; Manji H; Zandi MS; Wiethoff S
    J Neurol Sci; 2021 Sep; 428():117608. PubMed ID: 34391037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic COVID syndrome: Need for an appropriate medical terminology for long-COVID and COVID long-haulers.
    Baig AM
    J Med Virol; 2021 May; 93(5):2555-2556. PubMed ID: 33095459
    [No Abstract]   [Full Text] [Related]  

  • 16. Electrophysiological and neuroimaging tools to evaluate neurological symptoms, manifestations, and complications in patients with long COVID-19.
    Luvizutto GJ; Bazan R
    Neurol Neurochir Pol; 2023; 57(1):8-10. PubMed ID: 36515147
    [No Abstract]   [Full Text] [Related]  

  • 17. Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients.
    Yachou Y; El Idrissi A; Belapasov V; Ait Benali S
    Neurol Sci; 2020 Oct; 41(10):2657-2669. PubMed ID: 32725449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-acute neurological consequences of COVID-19: an unequal burden.
    Nolen LT; Mukerji SS; Mejia NI
    Nat Med; 2022 Jan; 28(1):20-23. PubMed ID: 35039657
    [No Abstract]   [Full Text] [Related]  

  • 19. Acute and post-acute neurological manifestations of COVID-19: present findings, critical appraisal, and future directions.
    Beghi E; Giussani G; Westenberg E; Allegri R; Garcia-Azorin D; Guekht A; Frontera J; Kivipelto M; Mangialasche F; Mukaetova-Ladinska EB; Prasad K; Chowdhary N; Winkler AS
    J Neurol; 2022 May; 269(5):2265-2274. PubMed ID: 34674005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19, ferrosenescence and neurodegeneration, a mini-review.
    Sfera A; Osorio C; Maguire G; Rahman L; Afzaal J; Cummings M; Maldonado JC
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110230. PubMed ID: 33373681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.